Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03435848 | Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy(ELPIS) | completed | Phase 2 | 66 | BioSight Ltd.INDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT03050216 | QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML | completed | Phase 2 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00045305 | Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes | completed | Phase 2 | 17 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02124746 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 87 | Sierra Oncology LLC - a GSK companyINDUSTRY | 5 | Jun 18, 2023 | clinicaltrials |
| NCT02098161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01806571 | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT03417154 | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | completed | Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT01611116 | Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia(TOR-AML) | completed | Phase 2 | 33 | Goethe UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT04146038 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | completed | Phase 2 | 5 | Rutgers, The State University of New JerseyOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT00413439 | Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy | completed | Phase 2 / Phase 3 | 18 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03349502 | MG4101 for Refractory or Relapsed AML | completed | Phase 2 | 11 | Seoul National University HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02878785 | Decitabine and Talazoparib in Untreated AML and R/R AML(1565GCC) | completed | Phase 1 / Phase 2 | 25 | University of Maryland, BaltimoreOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04173585 | TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib(TEAM) | completed | Phase 2 | 50 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02942173 | CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT | completed | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT00744081 | Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | completed | Phase 2 | 130 | Goethe UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02845297 | Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients | completed | Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT01238211 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Mar 1, 2023 | clinicaltrials |
| NCT01420926 | Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03303339 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT00796068 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant | completed | Phase 2 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02810990 | Bosutinib in Elderly Chronic Myeloid Leukemia(BEST) | completed | Phase 2 | 65 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML(SOPRA) | completed | Phase 2 | 317 | Karyopharm Therapeutics IncINDUSTRY | 11 | Jan 26, 2023 | clinicaltrials |
| NCT05048615 | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML | completed | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04926194 | Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm(DSC-SR) | completed | Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02996474 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 28, 2022 | clinicaltrials |
| NCT00423514 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | completed | Phase 1 / Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT00559091 | A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia(Borden-001) | completed | Phase 2 | 18 | Jewish General HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02126553 | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01850004 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response(DASFREE) | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 6 | Nov 3, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT04424147 | Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML | completed | Phase 2 | 96 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Oct 24, 2022 | clinicaltrials |
| NCT01700673 | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2023source: clinicaltrials